Clinical Trial Detail

NCT ID NCT03302247
Title Depletion of Myeloid Derived Suppressor Cells to Enhance Anti PD-1 Therapy
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements No
Sponsors Fox Chase Cancer Center
Indications

lung non-small cell carcinoma

Therapies

Nivolumab

Gemcitabine + Nivolumab

Age Groups: senior adult

No variant requirements are available.